Gut Microbiota Modulation
Conditions
Brief summary
This study aims to evaluate the safety and efficacy of the probiotic LH76 as a dietary supplement in healthy adults. The research will assess its effects on gut microbiota composition, intestinal health, and immune function compared to a placebo. Key outcomes include changes in microbial diversity, intestinal barrier integrity, and immune response markers over the intervention period. The findings will contribute to understanding the potential health benefits of LH76 and its role in supporting gut and immune health.
Interventions
DIETARY_SUPPLEMENTPlacebo
Every day to give 3 g maltodextrin intervention for 8 weeks. Store in a cool and dry place.
DIETARY_SUPPLEMENTprobiotic LH76
Intervention with LH76 (30 billion CFU/ day, 3g) was administered daily for 8 weeks. Store in a cool, dry place.
Sponsors
Wecare Probiotics Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Willing to undergo 3 follow-up visits during the intervention period Be willing to provide blood, urine and stool samples 2 times during the intervention period 2. Willing to self-administer probiotic or placebo once a day during the intervention period 3. Good eyesight, can read and write, can wear glasses 4. Have good hearing and be able to hear and understand all instructions during the intervention
Exclusion criteria
1. Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease) 2. Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia) 3. Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder 4. Take medication for depression or low mood Internal organ failure (heart, liver or kidney failure, etc.) 5. Have received radiation or chemotherapy in the past 6. Have undergone a general anesthesia procedure/procedure within the past three years, or plan to undergo a general anesthesia procedure/procedure within the next 3 months during this trial period 7. Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past Open Contacts/Locations
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Gut Microbiota Composition in Response to LH76 Supplementation | Week 0 and Week 8 | This study assesses the impact of LH76 supplementation on gut microbiota diversity and composition using high-throughput sequencing. The primary objective is to determine whether LH76 supplementation leads to significant improvements in gut microbiota balance compared to a placebo. Changes in microbial diversity, relative abundance of beneficial bacteria will be analyzed to assess the probiotic's effectiveness. |
Contacts
Primary ContactFei Xu, Dr.
Outcome results
None listed